Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 3:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 1,891 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Prostate Cancer Patients Clear all
Active, not recruiting Phase 2 Interventional Results available

pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer

NCT03600350
View directory record Official record
Conditions
Prostate Cancer
Interventions
pTVG-HP, Nivolumab, GM-CSF
Biological · Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 31, 2026, 3:23 AM EDT
Terminated Phase 1 Interventional

Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer

NCT00512668
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Interventions
leuprolide acetate, goserelin acetate, bicalutamide, nilutamide, flutamide, temsirolimus, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2013 · Synced Oct 31, 2026, 3:23 AM EDT
Completed Phase 3 Interventional Results available

Study of Diagnostic Performance of [18F]CTT1057 in BCR

NCT04838613
View directory record Official record
Conditions
Prostatic Neoplasms, Prostate Cancer, Recurrence
Interventions
[18F]CTT1057, [68Ga]Ga-PSMA-11
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 31, 2026, 3:23 AM EDT
Completed Phase 1 Interventional

A Pilot Study Evaluating Oral Triamcinalone in Patients With Androgen Independent Prostate Cancer

NCT00186108
View directory record Official record
Conditions
Prostate Cancer
Interventions
Oral Triamcinalone
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 25, 2007 · Synced Oct 31, 2026, 3:23 AM EDT
Completed Not applicable Interventional

Decision Support Interventions (DESI) for Prostate Cancer Screening and Treatment - Study 2

NCT01244568
View directory record Official record
Conditions
Prostate Cancer
Interventions
Prostate cancer treatment DESI
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
45 Years and older · Male only
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Palo Alto, California • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 23, 2014 · Synced Oct 31, 2026, 3:23 AM EDT
Terminated Phase 2 Interventional Results available

Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer

NCT02494713
View directory record Official record
Conditions
Prostate Cancer
Interventions
Degarelix, Doxorubicin, Ketoconazole, Docetaxel, Estramustine
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 27, 2018 · Synced Oct 31, 2026, 3:23 AM EDT
Active, not recruiting No phase listed Observational

A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described

NCT04122976
View directory record Official record
Conditions
Prostate Cancer
Interventions
Darolutamide(Nubeqa, BAY1841788)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
805 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
24
States / cities
Homewood, Alabama • Tucson, Arizona • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 31, 2026, 3:23 AM EDT
Completed Phase 3 Interventional Results available

Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer

NCT03274687
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7
Interventions
Hypofractionated Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Radiation Therapy
Radiation · Other
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
229
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 188 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 31, 2026, 3:23 AM EDT
Terminated Not applicable Interventional

Guided Biopsy for Mapping Prostate Cancer

NCT01007214
View directory record Official record
Conditions
Prostate Cancer
Interventions
Prostatectomy
Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 27, 2014 · Synced Oct 31, 2026, 3:23 AM EDT
Terminated Phase 2 Interventional

Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer

NCT04754425
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Adenocarcinoma, Metastatic Prostate Small Cell Neuroendocrine Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Biopsy, Biospecimen Collection, Erdafitinib
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 31, 2026, 3:23 AM EDT
Completed Not applicable Interventional

Robust Evaluation to Measure Improvements in Nonadherence From Low-cost Devices

NCT02015806
View directory record Official record
Conditions
Cardiovascular Disease, Diabetes, Breast Cancer, Depression, Mental Health Disorder, Prostatic Hypertrophy, Benign, Parkinson's Disease, Epilepsy
Interventions
RxTimerCap, Take-N-Slide, Pillbox
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 64 Years
Enrollment
53,480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Woonsocket, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 11, 2016 · Synced Oct 31, 2026, 3:23 AM EDT
Completed Phase 2 Interventional

Perillyl Alcohol in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00003238
View directory record Official record
Conditions
Prostate Cancer
Interventions
perillyl alcohol
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
Up to 120 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
8
States / cities
Freeport, Illinois • Green Bay, Wisconsin • Janesville, Wisconsin + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2019 · Synced Oct 31, 2026, 3:23 AM EDT
Completed Phase 1 Interventional

A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer

NCT01300533
View directory record Official record
Conditions
Metastatic Cancer, Cancer, Solid Tumors
Interventions
BIND-014
Drug
Lead sponsor
BIND Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
6
States / cities
Scottsdale, Arizona • Greenbrae, California • Los Angeles, California + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2016 · Synced Oct 31, 2026, 3:23 AM EDT
Completed Phase 1 Interventional Results available

A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer

NCT04148937
View directory record Official record
Conditions
Advanced Cancer
Interventions
LY3475070, Pembrolizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
7
States / cities
Denver, Colorado • Lake Mary, Florida • Grand Rapids, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2024 · Synced Oct 31, 2026, 3:23 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery

NCT03809000
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiation Therapy, Enzalutamide, Bicalutamide, GnRH analog
Radiation · Drug
Lead sponsor
RTOG Foundation, Inc.
Other
Eligibility
18 Years and older · Male only
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
106
States / cities
Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 89 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 31, 2026, 3:23 AM EDT
Completed Phase 4 Interventional

The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy

NCT00063609
View directory record Official record
Conditions
Prostate Cancer
Interventions
zoledronic acid
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
44
States / cities
Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Oct 31, 2026, 3:23 AM EDT
Completed Not applicable Interventional Results available

Internal Radiation Therapy in Treating Patients With Prostate Cancer

NCT00573833
View directory record Official record
Conditions
Prostate Cancer
Interventions
questionnaire administration, quality-of-life assessment, brachytherapy
Other · Procedure · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 20, 2017 · Synced Oct 31, 2026, 3:23 AM EDT
Completed Phase 1Phase 2 Interventional

Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory Prostate Cancer

NCT00151086
View directory record Official record
Conditions
Prostate Cancer
Interventions
Estramustine, Vinorelbine
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 22, 2015 · Synced Oct 31, 2026, 3:23 AM EDT
Completed Phase 2 Interventional Results available

S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer

NCT00028769
View directory record Official record
Conditions
Prostate Cancer
Interventions
bicalutamide, estramustine, etoposide, flutamide, goserelin, leuprolide, nilutamide, paclitaxel
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Male only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
91
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2013 · Synced Oct 31, 2026, 3:23 AM EDT
Completed Phase 1 Interventional

Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors

NCT00313599
View directory record Official record
Conditions
Bladder Cancer, Brain and Central Nervous System Tumors, Breast Cancer, Esophageal Cancer, Extragonadal Germ Cell Tumor, Gastric Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer
Interventions
lapatinib, paclitaxel
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2014 · Synced Oct 31, 2026, 3:23 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel

NCT03419234
View directory record Official record
Conditions
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma in the Soft Tissue, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions
Abiraterone Acetate, Androgen deprivation therapy, Cabazitaxel, Prednisone
Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older · Male only
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
665
States / cities
Fairbanks, Alaska • Goodyear, Arizona • Kingman, Arizona + 437 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 31, 2026, 3:23 AM EDT
Terminated Not applicable Interventional

Hypertension Management in Cancer Patients

NCT03919214
View directory record Official record
Conditions
Blood Pressure, Hypertension, Cancer, Cancer, Breast, Cancer of Prostate, CLL, Hematopoietic Malignancy
Interventions
Automated Messaging
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years to 74 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 19, 2023 · Synced Oct 31, 2026, 3:23 AM EDT
Terminated Phase 2 Interventional

Antineoplaston Therapy in Treating Patients With Metastatic Prostate Cancer

NCT00003533
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
Antineoplaston therapy (Atengenal + Astugenal)
Drug
Lead sponsor
Burzynski Research Institute
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1999
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 31, 2026, 3:23 AM EDT
Completed Not applicable Interventional

Magnetic Resonance Imaging-Transrectal Ultrasound Fusion Image-Guided Prostate Biopsy Following Radical Prostatectomy in Patients With Prostate Cancer

NCT01764347
View directory record Official record
Conditions
Prostate Cancer
Interventions
therapeutic conventional surgery, ultrasound-guided prostate biopsy, magnetic resonance imaging
Procedure
Lead sponsor
University of Southern California
Other
Eligibility
Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2014 · Synced Oct 31, 2026, 3:23 AM EDT